

Silco Pharmaceuticals Limited

Un-Audited Financial Statements (Third Quarter)

For the period from 1st July 2023 to 31 March 2024


Silco Pharmaceuticals Limited
Statement of Financial Position (Un-Audited)
As at March 31, 2024

Particulars	Notes	Amount in Taka	
		31 March 2024	30 June 2023
Assets			
Non Current Assets		1,749,406,510	1,762,417,380
Property, Plant and Equipment	3.00	1,587,771,177	1,587,456,216
Right of Use Assets	4.00	10,400,095	-
Capital Work-in-Progress	5.00	151,235,239	174,961,164
Current Assets		1,068,225,679	1,004,930,028
Inventories	6.00	440,365,511	444,141,973
Trade and Other Receivables	7.00	417,998,305	377,507,323
Advances, Deposits and Prepayments	8.00	147,638,783	133,547,946
Cash and Cash Equivalents	9.00	58,520,479	30,764,262
Investment In Share	10.00	3,702,600	18,968,523
Total Assets		2,817,632,189	2,767,347,407
Shareholders Equity and Liabilities			
Shareholders Equity		2,349,130,550	2,319,852,389
Share Capital	11.00	1,038,070,000	1,038,070,000
Unrealized Gain/Loss on Marketable Securities		769,234	(6,915,207)
Retained Earnings	12.00	1,310,291,316	1,288,697,596
Non-Current Liabilities		161,881,038	151,734,305
Lease Liabilities (Non Current Portion)		9,567,386	-
Deferred Tax Liabilities	13.00	152,313,652	151,734,305
Current Liabilities		306,620,601	295,760,714
Trade and Other Payable	14.00	9,521,785	9,749,939
Lease Liabilities (Current Portion)	15.00	1,084,209	-
Payable to IPO Applicants		184,493	184,607
Provision for Expenses	16.00	5,858,143	6,322,574
Liabilities for contribution to WPPF	17.00	2,586,875	3,342,966
Dividend Payables (Unclaimed)	18.00	2,299,748	2,458,950
Provision for income tax	19.00	285,085,349	273,701,678
Total Shareholders Equity and Liabilities		2,817,632,189	2,767,347,407
Net Asset Value (NAV) per Share	27.00	22.63	22.35

The annexed notes form an integral part of these financial statements.

নাইম সাহেব

Chairman




Managing Director



Director



Company Secretary



Chief Financial Officer

SIGNED IN TERMS OF OUR ANNEXED REPORT OF EVEN DATE

Date: April 29, 2024

Place: Dhaka


Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income (Un-Audited)
For the period ended March 31, 2024

Particulars	Notes	Amount in Taka			
		01 July 2023 to 31 Mar. 2024	01 July 2022 to 31 Mar. 2023	01 Jan 2024 to 31 Mar. 2024	01 Jan 2023 to 31 Mar. 2023
Turnover	20.00	317,002,396	359,863,947	109,965,822	124,228,048
Less: Cost of Goods Sold	21.00	208,773,030	232,167,729	74,274,827	76,597,869
Gross Profit/(Loss)		108,229,366	127,696,218	35,690,995	47,630,179
Less: Operating Expenses	22.00	53,152,177	59,671,125	16,978,974	19,826,953
Profit from Operation		55,077,188	68,025,093	18,712,021	27,803,225
Less: Financial Expenses	23.00	48,466	84,479	8,311	26,701
Less: Financial Expenses (Lease)		704,348	179,676	245,391	37,927
Non-operation Income	24.00	877,827	23,170,564	4,503,168	1,639,035
Profit before Contribution to WPPF		55,202,202	90,931,502	22,961,487	29,377,632
Less: Workers' Profit Participation/Welfare Fund (WPPF)		2,586,875	4,330,072	878,968	1,398,935
Profit before Income Tax		52,615,327	86,601,430	22,082,519	27,978,698
Less: Provision for Income Tax	25.00	11,963,018	19,484,610	4,968,567	6,294,495
Current Tax		11,383,670	11,280,820	4,680,078	2,774,154
Deferred Tax		579,347	8,203,790	288,489	3,520,342
Net Profit after Tax (Transferred to Retained Earning)		40,652,309	67,116,820	17,113,952	21,684,202
Other Comprehensive Income:					
Unrealized Gain/Loss on Investment		7,684,441	(137,174)	807,674	4,184,349
Total Comprehensive income		48,336,750	66,979,646	17,921,626	25,868,551
Earnings per Share (EPS)	26.00	0.39	0.65	0.16	0.21

The annexed notes form an integral part of these financial statements.

সাইফুল আলম

Chairman



Managing Director



Director



Company Secretary



Chief Financial Officer

Date: April 29, 2024

Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the period ended March 31, 2024

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2023	1,038,070,000	(6,915,207)	1,288,697,596	2,319,852,389
Net Profit/(Loss) during the period	-	-	40,652,309	40,652,309
Declared 3% Cash Dividend			(19,058,589)	(19,058,589)
Unrealized Gain/Loss on Marketable Shares	-	7,684,441		7,684,441
Balance as on March 31, 2024	1,038,070,000	769,234	1,310,291,316	2,349,130,550

Statement of Changes in Equity
For the period ended March 31, 2023

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2022	1,038,070,000	(10,687,292)	1,251,240,627	2,278,623,335
Net Profit/(Loss) during the period	-	-	67,116,820	67,116,820
Declared 5% Cash Dividend			(31,764,315)	(31,764,315)
Unrealized Gain/Loss on Marketable Shares	-	(137,174)	-	(137,174)
Balance as on March 31, 2023	1,038,070,000	(10,824,466)	1,286,593,133	2,313,838,667

নাজমুল হক (চম)

Chairman



Managing Director



Director



Company Secretary



Chief Financial Officer


Date: April 29, 2024

Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Cash Flows (Un-Audited)
For the period ended March 31, 2024


Particulars	Notes	Amount in Taka	
		01 July 2023 to 31 Mar. 2024	01 July 2022 to 31 Mar. 2023
A. Cash Flows from Operating Activities			
Cash received from Customers	31.00	276,511,414	380,052,381
Cash received from Non-operating income		1,594,871	3,864,322
Cash Paid to Suppliers	32.00	(124,666,717)	(129,006,346)
Cash Paid to Employees	33.00	(47,814,127)	(48,625,643)
Cash Paid to Others	34.00	(30,581,151)	(46,051,709)
Financial Expenses		(48,466)	(84,479)
Income Tax Paid		(4,022,791)	(5,992,895)
Net cash flows from operating activities		70,973,034	154,155,630
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(1,798,600)	(2,980,960)
Cash Payment for Capital Work-in-Progress		(40,514,086)	(157,968,304)
Gain/(Loss) on Investment		(717,044)	19,306,242
Investment in Share		22,950,364	21,943,578
Net cash used in investing activities		(20,079,366)	(119,699,444)
C. Cash Flows from Financing Activities			
Refund to IPO Applicants (Bank Charge)		(114)	(121)
Financial Expenses (Lease)		(704,348)	(179,676)
Principle payment (Lease)		(3,215,197)	(3,050,982)
Cash dividend paid		(19,217,791)	(31,287,875)
Net Cash used for financing activities		(23,137,450)	(34,518,653)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		27,756,217	(62,467)
E. Cash and Cash Equivalents at the beginning of the period		30,764,262	26,719,260
F. Cash and Cash Equivalents at the end of the period (D+E)		58,520,479	26,656,793
Net Operating Cash Flows Per Share (NOCFPS)	28.00	0.68	1.49


Chairman


Managing Director


Director


Company Secretary


Chief Financial Officer

Date: April 29, 2024
Place: Dhaka